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Abstract
Objective: To evaluate the association of the BRAFV600E mutation with sonographic features and clinicopathologic
characteristics in a large population with conventional papillary thyroid carcinoma (PTC).
Methods: We retrospectively reviewed the sonographic features, clinicopathologic characteristics, and presence of the
BRAFV600E mutation in 688 patients who underwent thyroidectomy for conventional PTC between January and July 2010 at
a single institution. The incidence of the BRAFV600E mutation was calculated. The sonographic features and clinicopathologic
characteristics were compared between BRAF-positive and BRAF-negative patients. BRAF-positive patients were subdivided
into those with papillary thyroid microcarcinoma (the PTMC group) and those with PTC larger than 10 mm (the PTC.
10 mm group), and their sonographic features were compared.
Results: The BRAFV600E mutation was detected in 69.2% of patients (476 of 688). Sonographic features were not significantly
different between BRAF-positive and BRAF-negative PTC, nor between PTMC and PTC.10 mm groups. The BRAFV600E
mutation was associated with male sex (P= 0.028), large tumor size, extrathyroidal extension, central and lateral lymph node
metastasis, and advanced tumor stage (P,0.0001).
Conclusion: The BRAFV600E mutation was significantly associated with several poor clinicopathologic characteristics, but was
not associated with sonographic features, regardless of tumor size. We recommend that patients with a thyroid nodule with
any suspicious sonographic feature undergo preoperative BRAFV600E testing for risk stratification and to guide the initial
surgical approach in PTC.
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Introduction
Papillary thyroid carcinoma (PTC) is the most common thyroid
cancer, accounting for 85-90% of cases, with an increasing
incidence globally [1,2]. The development of high-resolution
ultrasonography (US) has contributed to the detection and
diagnosis of PTC with high specificity, but relatively low sensitivity
[3,4]. US-guided fine-needle aspiration (US-FNA) biopsy is a
standard tool for diagnosing thyroid malignancies preoperatively
with high specificity. Its major limitation, however is the 15–25%
rate of indeterminate cytology (Bethesda category I-nondiagnostic
or category III- atypia of undetermined significance or follicular
lesion of undetermined significance) [5].
Various genetic analyses have improved the diagnostic perfor-
mance of US-FNA. Above all, the B-type Raf kinase (BRAF)
mutation has received the most attention in recent years because
of its high prevalence and high specificity for PTC. The BRAF
mutation induces aberrant activation of the mitogen-activated
protein kinase pathway, which plays a fundamental role in cell
proliferation, differentiation, and apoptosis, finally resulting in
tumorigenesis [1,6,7]. The T1799A point BRAF mutation is the
most common mutation found in the BRAF gene, accounting for
more than 90% of mutations. It causes a V600E amino acid
change in the BRAF protein, resulting in a BRAFV600E mutation
that occurs exclusively in PTC with a prevalence ranging from 29
to 83% [1,7]. Several previous reports have demonstrated that
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BRAFV600E mutation testing may enhance the diagnostic accuracy
of US-FNA for PTC [8–13].
The roles of the BRAFV600E mutation have been found to
include the down-regulation of tumor suppressor genes, up-
regulation of tumor-promoting molecules, and resulting promotion
of tumor growth, angiogenesis, tissue invasion and metastasis [6].
In addition, a number of reports have demonstrated a direct
association of the BRAFV600E mutation with poor prognostic
factors such as extrathyroidal extension, lymph node and distant
metastases, advanced tumor stage, and tumor recurrence,
although it remains controversial [14–28]. Several studies have
also found a positive correlation between the BRAFV600E mutation
and suspicious sonographic features of thyroid nodules [11–29].
However, only a few reports have been published on the
association between the BRAFV600E mutation and sonographic
features in PTC; findings have varied according to tumor size
[2,13,30,31].
Therefore, we evaluated the association of the BRAFV600E
mutation with sonographic features and clinicopathologic charac-
teristics in a large-scale study population with conventional PTC.
Materials and Methods
The institutional review board of Gangnam Severance hospital
approved of this retrospective observational study and required
neither patient approval nor informed consent for our review of
patients’ images and records. However, written informed consent
was obtained from all patients for US-FNA and BRAFV600E
mutation analysis prior to each procedure as a daily practice.
Patients
Our hospital’s institutional review board approved this retro-
spective observational study and waived the requirement for
informed consent. Between January and July 2010, 939 consec-
utive patients underwent thyroidectomy and were diagnosed with
conventional PTC at our institution. Of these, 251 patients were
excluded for the following reasons: patient refusal of BRAFV600E
mutation analysis of the surgical specimen (n = 87), lack of
preoperative US at our institution (n= 161) and inability to
identify the lesion on US (n= 3). A total of 688 patients were
included in this study (553 women and 135 men; mean age, 45
years; range, 17–83).
All patients were diagnosed preoperatively with malignancy by
US-FNA at our institution (n= 222) or outside clinics (n = 466).
US-FNA was performed on all suspicious thyroid nodules larger
than 5 mm, and on nodules smaller than 5 mm at the patient’s or
clinician’s request. Cytologic results were as follows: 531 papillary
carcinomas, 147 cases suspicious for papillary carcinoma, 8 cases
with atypia of undetermined significance, 1 benign follicular
nodule, and 1 lymphocytic thyroiditis. Eight atypical lesions were
surgically removed due to sonographic features compatible with
papillary carcinoma (n= 7) or histologic confirmation of malig-
nancy through core biopsy (n = 1). Two benign cases were
surgically removed due to sonographic feature compatible with
papillary carcinoma and lymph node metastasis on US-FNA.
All patients received curative surgery with either total thyroid-
ectomy (n= 517) or near-total thyroidectomy (n= 171). Prophy-
lactic or therapeutic central-compartment neck dissection was
performed for all patients. Lateral compartmental lymph node
dissection was performed for patients with US-FNA-proven or
clinically suspicious lateral cervical lymphadenopathy (n = 61).
Ultrasound examination
US images were obtained using either HDI5000 or IU22
ultrasound scanners (Philips Healthcare, Bothell, WA) equipped
with a 7.5–12 MHz linear array transducer. Four radiologists who
specialize in thyroid US with between 1 and 12 years of experience
(E.J.S., J.A.K., J.H.Y., and A.Y.P.) performed all US examinations
before BRAFV600E mutation analysis was conducted. Two
radiologists (A.Y.P and E.J.S, with 1 and 12 years of experience,
respectively) blinded to BRAF status retrospectively analyzed the
following sonographic features in consensus: tumor size, compo-
sition (solid or cystic), echogenicity with respect to the thyroid
parenchyma and strap muscle (hyperechoic, isoechoic, hypoechoic
or markedly hypoechoic), margin (circumscribed, microlobulated
or irregular), calcifications (microcalcification, macrocalcification,
or negative), and shape (parallel or nonparallel). US findings of
microcalcification, irregular or microlobulated margin, marked
hypoechogenicity, and nonparallel shape are considered indicative
of malignancy. Final assessment category was classified according
to the number of suspicious features, which was based on the
modified thyroid imaging reporting and data system (TIRADS)
suggested by Kwak et al. (4): probably benign (no suspicious US
feature), low suspicion for malignancy (1 suspicious feature),
intermediate suspicion for malignancy (2 suspicious feature),
moderate suspicion for malignancy (3 suspicious features) or
highly suggestive of malignancy (4 suspicious features).
Clinicopathologic data analysis
Medical records were reviewed to determine sex and age at
diagnosis. Pathology reports were reviewed for the following data:
tumor size, presence of BRAFV600E mutation, multifocality,
extrathyroidal extension, and central or lateral lymph node
metastasis. TNM stage was assigned based on the AJCC Cancer
Staging Manual 7th edition [32]. Patients were divided into two
groups according to pathologic tumor size less than 10 mm
(papillary thyroid microcarcinoma, PTMC group) or greater than
10 mm (PTC.10 mm group).
BRAFV600E mutation analysis
DNA was extracted from 10-mm-thick sections of paraffin
blocks using the QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden,
Germany). DNA was extracted only from the marked tumor
tissue. The presence of a BRAF mutation was evaluated by
polymerase chain reaction-restriction fragment length polymor-
phism (PCR-RFLP) or direct sequencing. For PCR-RFLP, a 50-
mL PCR mixture was composed of extracted DNA at 100 ng/mL,
5 U Taq polymerase, 0.25 mM dNTP, 20 pmol of primers, and
106Ex Taq buffer. To examine the BRAF exon 15, a primer that
created a restriction site for the BspE1 enzyme was designed. The
PCR conditions were as follows: denaturation at 95uC for 10
minutes, followed by 40 cycles at 94uC for 30 seconds, 45uC for 30
seconds, 72uC for 30 seconds, and a final extension step at 72uC
for 10 minutes. The PCR product was purified with the MinElute
PCR purification kit (Qiagen), digested with 10 units of BspE1
(Takara, Tokyo, Japan) and electrophoresed in a 4% agarose gel
containing ethidium bromide. The stained gel was photographed
using an ultraviolet light transilluminator. For direct sequencing,
BRAF exon 15, which contains the codon encoding the V600E
mutation, was amplified. The PCR conditions were as follows:
denaturation at 94uC for 5 minutes, followed by 40 cycles at 94uC
for 20 seconds, 56uC for 30 seconds, 72uC for 30 seconds, and a
final extension step at 72uC for 5 minutes. PCR products were
purified using the Exo I/SAP Clean-Up protocol (Hilden,
Germany), and direct DNA sequencing was performed using the
BRAF and Clinical Factors of Thyroid Cancer
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3730 Big Dye Terminator v 3.1 Sequencing Standard (Applied
Biosystems, Foster City, CA).
Statistical analysis
The incidence of the BRAFV600E mutation was calculated.
Sonographic features and clinicopathologic characteristics were
compared between the patients with and without the BRAFV600E
mutation. The correlation between sonographic features and the
BRAFV600E mutation was also evaluated in the PTMC and PTC.
10 mm groups. The chi-squared or Fisher’s exact test was used for
categorical variables and the Student’s t-test was used for
continuous variables. Multivariate logistic regression analysis was
performed for the association of the BRAFV600E mutation with
sonographic features in patients with PTC. Statistical significance
was accepted for P-values less than 0.05. All statistical analysis was
performed using SPSS version 19.0 (SPSS, Inc., Chicago, IL).
Results
Of the 688 patients with PTC, 514 (71.4%) had PTMC, 174
(28.6%) had PTC.10 mm, and 476 (69.2%) had the BRAFV600E
mutation. The incidence of the BRAFV600E mutation was
significantly higher in the PTC.10 mm group than the PTMC
group (81.0% vs. 65.2%, P,0.0001)
Sonographic features
BRAF-positive PTC were significantly larger than BRAF-
negative PTC on US (10.866.8 mm vs. 8.464.9 mm, P,
0.0001). There were no significant differences in sonographic
features between BRAF-positive and BRAF-negative PTC,
including composition, echogenicity, margin, calcification, shape
or final assessment (Table 1). Multivariate logistic regression
analysis also showed no association between the BRAFV600E
mutation with suspicious sonographic features (Table 2).
BRAF-positive PTMC were significantly larger than BRAF-
negative PTMC (8.063.8 mm vs. 7.162.7 mm, P=0.004).
However, there was no significant difference in size according to
the BRAFV600E mutation in the PTC,10 mm group
(17.767.4 mm vs. 15.667.5 mm, P=0.164). In addition, there
were no significant differences in other sonographic features
according to the BRAFV600E mutation in either the PTMC or
PTC.10 mm group (Table 1). Large lesion size was an indepen-
dent predictive factor for BRAF positivity on multivariate analysis
(Odds ratio [95% confidence interval]; 1.102 [1.058–1.148], P,
.0001) (Table 2).
Clinicopathologic characteristics
Compared to BRAF-negative patients, BRAF-positive patients
were more likely to be male (21.8% vs. 14.6%, P=0.028) and to
have a larger pathologic tumor size (9.165.9 mm vs.
6.664.2 mm, P,0.0001).
The associations between the BRAFV600E mutation and
clinicopathologic characteristics are summarized in Table 3.
BRAF-positive PTC presented more frequently with extrathyr-
oidal extension compared to BRAF-negative PTC (64.1% vs.
43.9%, P,0.0001). Lymph node metastases (central/lateral) were
significantly more frequent in BRAF-positive than BRAF-negative
PTC (31.1/10.9% vs. 17.9/5.2%, P,0.0001). Also, BRAF-
positive PTC were more likely to present at a higher (III/IV)
TNM stage compared to BRAF-negative PTC (31.1/42.2% vs.
29.2/23.1%, P,0.0001). There were no significant differences in
age or lesion multiplicity according to BRAF status.
Discussion
Previous meta-analyses have published values for the overall
prevalence of the BRAFV600E mutation ranging from 29 to 83%
[7,14–16]. This wide range may be due to variations in PTC
subtype, subjects’ geographical backgrounds, and research meth-
odology. Korea appears to have a relatively high frequency of the
BRAFV600E mutation, ranging from 52 to 83% [14,15,23,25,33].
Our large-scale study of conventional PTC in Korea also found a
relatively high prevalence of 69.2%.
In regards to the association between the BRAF mutation and
sonographic features of PTC, two recent studies reported no
significant difference in sonographic features between BRAF-
positive and BRAF-negative PTC [2,13]. A Korean study on
PTMC alone also reported no significant difference [31]. In
contrast, a recent study on 115 patients with PTC larger than
10 mm found that BRAF-positivity was associated with suspicious
sonographic findings and the number of suspicious features has
positive correlation with the risk of BRAF positivity [30]. The
authors suggested that difficulties in accurate sonographic
characterization of small PTC confounded studies including small
PTC. However, our study found no significant difference in any
sonographic feature between BRAF-positive and BRAF-negative
PTC in the PTC.10 mm group as well as PTMC group. Final
assessment category classified according to the number of
suspicious features was also not significantly different between
BRAF-positive and BRAF-negative PTC, although the PTC.
10 mm group had more tendency in correlation between BRAF-
positivity and final assessment category than PTMC group did (P-
value, 0.065 vs. 0.500). We assume that such discrepancy might
result from different study population between ours and the above-
mentioned study. Most suspicious sonographic features used in
both studies are oriented to diagnosis of conventional PTC,
therefore only inclusion of conventional PTC in our study may
predispose little distinction of sonogrpahic features between
BRAF-positive and BRAF-negative PTC. The result of our study
suggests that there is no specific sonographic feature to be an
indication for performing additional BRAFV600E mutation analysis
to FNA for the thyroid nodules suspicious of PTC.
The tumor size of BRAF-positive PTC, both sonographic and
pathologic, were larger than that of BRAF-negative PTC. Previous
studies have also reported an association between the BRAF
mutation and large tumor size, which suggests the possibility that
the mutation induces tumor progression and aggressiveness
[23,26,34,35]. However, other studies have reported conflicting
results [2,14,18,22,33], indicating that the relationship between
the BRAF mutation and tumor size remains controversial. Our
results also showed that the BRAF mutation was more frequent in
men, consistent with previous studies [26,36].
In respect to the relationship between the BRAF mutation and
clinicopathologic PTC characteristics, many studies have reported
that one or more high-risk clinicopathologic parameters were
associated with the BRAF mutation [14–28]. Two recent meta-
analyses that included 5655 and 2470 PTC patients, respectively,
found a significant association between the BRAF mutation and
lymph node metastasis, extrathyroidal extension, advanced tumor
stage and recurrence [15,16]. In addition, a recent study with a
median 15 years of follow-up demonstrated that the BRAF
mutation was related to advanced tumor stage, vascular invasion,
and mortality [19]. Our results also revealed a relationship
between BRAF-positive PTC and high-risk clinicopathologic
characteristics, including extrathyroidal extension, lymph node
metastasis and advanced tumor stage. On the contrary, several
studies employing multivariate analysis with adjustment of
BRAF and Clinical Factors of Thyroid Cancer
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confounders found no such relationship with these characteristics
[14,33,37–39]. Possible reasons for this discrepancy in results
include variations in PTC subtypes, geographic or ethnic factors,
scale of enrolled data, disease extent at the time of diagnosis,
methodology of BRAF analysis, and the use of prophylactic central
neck compartment dissection.
Our study has several unique strengths. First, this is the largest
single-center study on conventional PTC, which limits participant
heterogeneity and variations in tumor subtypes. Second, our
finding that the BRAF mutation was associated with poor
clinicopathologic parameters suggests the utility of preoperative
BRAF analysis in risk stratification and surgical management,
especially in cases of equivocal extrathyroidal extension or cervical
node metastasis on preoperative US, or nondiagnostic result of
cervical lymph node metastasis on US-FNA. Lastly, we analyzed
the relationship between BRAF mutation and sonographic
features in both PTMC and PTC.10 mm groups to establish
the previous controversial results according to the tumor size and
observed the result that there was no difference in sonographic
features between the BRAF-positive PTC and BRAF-negative
PTC in both PTMC and PTC.10 mm.
Our study has several limitations. First, this was a retrospective
observational study, a design that prevents long-term follow-up or
analysis of actual clinical outcomes. Second, we did not evaluate
interobserver variability of PTMC sonographic features, despite
known difficulty in accurate characterization of small tumors.
Finally, we did not evaluate the Doppler or elastographic tumor
findings, which can provide additional diagnostic information.
Future areas of research include prospective long-term follow-up
and Doppler or elastographic evaluation of PTC.
Conclusion
The BRAF mutation was not associated with particular
sonographic features in conventional PTC, regardless of tumor
size. However, the mutation was significantly associated with poor
clinicopathologic parameters including male gender, large tumor
size, extrathyroidal extension, lymph node metastasis and
Table 2. Multivariate analysis of the association of the BRAFV600E mutation with sonographic features in patients with PTC.
Odds ratio (95% CI) P-value
Sonographic ize (mm) 1.102 (1.058–1.148) ,.0001
Markedly hypoechoic vs Hyper-/Iso-/Hypoechoic 1.159 (0.815–1.649) .412
Irregular/microlobulated vs Circumscribed 0.974 (0.341–2.781) .961
Microcalcifications vs Negative/Macrocalcification 1.057 (0.726–1.539) .771
Non-parallel vs Parallel 0.603 (0.419–0.867) .006
95% CI = 95% confidence interval.
doi:10.1371/journal.pone.0110868.t002
Table 3. Association of the BRAFV600E mutation with clinicopathologic characteristics of patients with PTC.
BRAF-positive PTC (n=476) BRAF-negative PTC (n =212) P-value
Age* 45.2611.2 45.4611.2 .784
Sex Female 372 (78.2) 181 (85.4) .028
Male 104 (21.8) 31 (14.6)
Pathologic size (mm)* 9.165.9 6.664.2 ,.0001
PTMC 335 (70.4) 179 (84.4) ,.0001
PTC.10 mm 141 (29.6) 33 (15.6)
Multiplicity Negative 321 (67.4) 151 (71.2) .323
Positive 155 (32.6) 61 (28.8)
Extrathyroidal extension Negative 171 (35.9) 119 (56.1) ,.0001
Positive 305 (64.1) 93 (43.9)
Lymph node metastasis Negative 276 (58.0) 163 (76.9) ,.0001
Central 148 (31.1) 38 (17.9)
Lateral 52 (10.9) 11 (5.2)
Tumor stage I 125 (26.3) 101 (47.6) ,.0001
II 2 (0.4) 0 (0)
III 148 (31.1) 62 (29.2)
IV 201 (42.2) 49 (23.1)
III/IV 349 (73.3) 111 (52.3) ,.0001
Data are raw numbers, percentages are in parentheses.
Abbreviations: PTMC, papillary thyroid microcarcinoma; PTC, papillary thyroid carcinoma.
* Numbers present the mean6standard deviation.
doi:10.1371/journal.pone.0110868.t003
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advanced tumor stage. Our results suggest the utility of
preoperative BRAFV600E mutation analysis of thyroid nodules
with any suspicious sonographic feature for risk stratification and
determination of the initial surgical approach in PTC.
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